Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3b/4 Randomized Double Blind Study Of 5 Mg Of Tofacitinib With And Without Methotrexate In Comparison To Adalimumab With Methotrexate In Subjects With Moderately To Severely Active Rheumatoid Arthritis

NCT02187055 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT02187055
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02187055 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3b/4 Randomized Double Blind Study Of 5 Mg Of Tofacitinib With And Without Methotrexate In Comparison To Adalimumab With Methotrexate In Subjects With Moderately To Severely Active Rheumatoid Arthritis
Lead sponsor
Pfizer
Phase
Phase 4
Overall status
Completed
Start date
August 31, 2014
Completion date
December 31, 2016
Enrollment
1,152 (actual)
Sites
215

Conditions

As the registry lists them; a condition with its own page is linked.

rhematoid arthritis